KDKatrina Dobinda

Katrina Dobinda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Katrina Dobinda has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Causal roles of phenotypic age acceleration and metabolic health on dementia: a Mendelian randomisation and structure learning study

    by Alexandra Baousi, Katrina Dobinda, Jingqi Zhu, Xinzhu Yu, Kenneth R. Muir, Artitaya Lophatananon, Brian McMillan, Paul Clarkson, Eugene Y. H. Tang, Hui Guo

    Summary: Background: Phenotypic age acceleration (PhenoAgeAccel), derived from PhenoAge, and MetaboHealth are composite exposures of biological ageing and metabolic health associated with dementia-related outcomes. Whether these associations are causal and reflect the exposures, constituent biomarkers, or both remains unclear. Methods: This study included UK Biobank participants of White British genetic ancestry. MetaboHealth was derived from nuclear magnetic resonance (NMR) metabolomics and PhenoAgeAccel from clinical biomarkers and chronological age. Genome-wide association studies (GWAS) were conducted for MetaboHealth (n=272 568) and PhenoAgeAccel (n=274 077). Independent genome-wide significant variants were used as genetic instruments in two-sample Mendelian randomisation (MR) with FinnGen all-cause dementia summary statistics. Inverse-variance weighting was the primary MR method. Causal network analysis estimated relationships among constituent biomarkers and dementia. Findings: GWAS identified 126 and 141 independent genome-wide significant variants for MetaboHealth and PhenoAgeAccel, of which 109 and 141 were retained as genetic instruments. MR found no evidence of a causal effect of genetically predicted MetaboHealth (per unit: OR 0·83, 95% CI 0·49–1·42; p=0·51) or PhenoAgeAccel (per year: OR 0·99, 95% CI 0·95–1·02; p=0·44) on all-cause dementia, with consistent findings across sensitivity analyses and robust MR methods. Lower lymphocyte percentage and higher NMR-derived glucose had direct relationships with dementia in the joint constituent-biomarker network. Interpretation: MR provided no evidence that either composite exposure causally influenced dementia. The network prioritised lymphocyte percentage and NMR-derived glucose, supporting examination of composite exposures alongside their constituent biomarkers. Funding: NIHR, UKRI, MRC, UK Dementia Research Institute, Innovate UK, and European Union. Full funding details are provided in the acknowledgements. Research in context: Evidence before this study: We searched PubMed from database inception to July 11, 2026, without language restrictions, using combinations of the terms “dementia”, “Alzheimer’s disease”, “vascular dementia”, “biological ageing”, “phenotypic age”, “PhenoAge”, “PhenoAgeAccel”, “MetaboHealth”, “metabolomics”, “genome-wide association study”, “Mendelian randomisation”, and “causal network”. Previous GWAS characterised the genetic architecture of PhenoAgeAccel and MetaboHealth. Longitudinal studies linked PhenoAgeAccel, derived from PhenoAge, to incident all-cause, young-onset, and late-onset dementia, dementia subtypes, cognition, and brain structure; MetaboHealth was associated with poorer cognitive performance, 10-year cognitive decline, and reduced functional independence. Related PhenoAge-based measures have also been studied in relation to modifiable factors and intervention response. Genetic causal evidence remained limited: one two-sample MR study found no evidence that PhenoAgeAccel affected Alzheimer’s disease or vascular dementia, while previous causal-discovery research placed Phenotypic Age within a dementia network without examining its constituent biomarkers. Added value of this study: To our knowledge, this is the first study to genetically evaluate PhenoAgeAccel and MetaboHealth as composite exposures and then deconstruct their constituent biomarker relationships using causal network analysis in dementia. It also provides the first large-scale GWAS of MetaboHealth using the complete Phase 3 UK Biobank Nightingale dataset. The expanded GWAS identified additional loci and enlarged the available genetic instrument sets, while the network analysis resolved the constituent biomarker structure underlying both composite exposures. Implications of all available evidence: For causal investigation, analysing PhenoAgeAccel and MetaboHealth alongside their constituent biomarkers reveals relationships obscured within the composite exposures. This does not preclude their use for prediction or risk stratification. Lymphocyte percentage and NMR-derived glucose therefore warrant further investigation as potential indicators of immune and metabolic pathways relevant to dementia.

  • Open Access

    Data Source1 from Phase I Evaluation of Patients with Newly Diagnosed Glioblastoma Treated with Radiation, Nivolumab, and IDO1 Enzyme Inhibitor BMS-986205

    by Rimas V. Lukas, Lijie Zhai, Kristen L. Lauing, Miri Kim, Taylor Koch, Manon Penco-Campillo, Prashant Bommi, Karan Dixit, Priya Kumthekar, Laura Sharp, et al.

    Patient Demographics of those enrolled in the trial

  • Open Access

    Supplementary Figures1 from Phase I Evaluation of Patients with Newly Diagnosed Glioblastoma Treated with Radiation, Nivolumab, and IDO1 Enzyme Inhibitor BMS-986205

    by Rimas V. Lukas, Lijie Zhai, Kristen L. Lauing, Miri Kim, Taylor Koch, Manon Penco-Campillo, Prashant Bommi, Karan Dixit, Priya Kumthekar, Laura Sharp, et al.

  • Open Access

    Supplementary Tables1 from Phase I Evaluation of Patients with Newly Diagnosed Glioblastoma Treated with Radiation, Nivolumab, and IDO1 Enzyme Inhibitor BMS-986205

    by Rimas V. Lukas, Lijie Zhai, Kristen L. Lauing, Miri Kim, Taylor Koch, Manon Penco-Campillo, Prashant Bommi, Karan Dixit, Priya Kumthekar, Laura Sharp, et al.

  • Open Access

    Phase I Evaluation of Patients with Newly Diagnosed Glioblastoma Treated with Radiation, Nivolumab, and IDO1 Enzyme Inhibitor BMS-986205

    by Rimas V. Lukas, Lijie Zhai, Kristen L. Lauing, Miri Kim, Taylor Koch, Manon Penco-Campillo, Prashant Bommi, Karan Dixit, Priya Kumthekar, Laura Sharp, et al.

    Purpose: We conducted a phase I trial to evaluate radiotherapy (RT) and nivolumab with the further addition of an indoleamine 2,3-dioxygenase 1 (IDO1) enzyme inhibitor (BMS-986205) in newly diagnosed patients with glioblastoma (GBM) IDH wild-type. Patients and Methods: In the current study, there were two primary cohorts of individuals. Cohort A included patients with O6-methylguanine-DNA methyltransferase (MGMT)–unmethylated GBM who received RT with concurrent and adjuvant nivolumab with escalating BMS-986205 doses. Cohort B included patients with MGMT-methylated GBM who received BMS-986205 at 25 mg daily with RT, nivolumab, and temozolomide (TMZ) followed by adjuvant TMZ. Patient outcomes were correlated with flow cytometric, transcriptome, general metabolite, and microbial metabolite analyses. Results: The treatments for both cohorts were moderately safe and tolerable. The treatment-emergent adverse events (TEAE) were mostly related to RT, TMZ, or the underlying disease and tumor progression. In cohort A, serious adverse events and TEAEs were predominantly lower grade, with no differences between the IDO1 enzyme inhibitor dosing cohorts. Dose-limiting toxicities reflected by increased transaminases (grade 3) were observed in two and three patients at the 50 and 100 mg levels of BMS-986205, respectively, with malaise observed in the 50 mg arm only. The 50 mg daily schedule was established as the recommended phase II dose (RP2D) in combination with RT and nivolumab. A number of exploratory correlative studies were also conducted. Conclusions: This single-arm, small phase I trial establishes a safety profile and RP2D for RT in combination with nivolumab and BMS-986205 for newly diagnosed patients with MGMT-unmethylated GBM (ClinicalTrials.gov: NCT04047706).


  • Open Access

    Clinical and Molecular Differences Suggest Different Responses to Immune Checkpoint Inhibitors in Microsatellite-Stable Solid Tumors with High Tumor Mutational Burden

    by Imran Nizamuddin, Tarik Demir, Katrina Dobinda, Ruohui Chen, Masha Kocherginsky, Peter Doukas, Neelima Katam, Carolyn Moloney, Devalingam Mahalingam

    Background/Objectives: We aim to identify predictors of response to ICIs in patients with advanced solid tumors that exhibiting a TMB ≥ 10 mut/Mb. Methods: Patients treated with ICIs alone at Northwestern University between 1 January 2015 and 31 December 2020 were identified. Progression-free survival (PFS) and overall survival (OS) were calculated using the Kaplan–Meier method, and groups were compared using the log-rank test. Wilcoxon rank sum tests, chi-squared tests, and Fisher’s exact tests were used for univariable analyses evaluating the impact of clinical and genetic variables on response, with significance defined as p < 0.05. Results: A total of 117 patients were classified as ICI-sensitive (n = 88) or non-ICI-sensitive (n = 29). Among evaluable patients (n = 105), the overall response rate was 34% with 14% achieving a complete response. Median PFS and OS were 8.05 months and 26.8 months, respectively. Higher PFS rates were significantly linked to the ICI-sensitive tumor group (p = 0.009), absence of liver metastasis (p = 0.015), and no prior systemic treatment (p = 0.001) in both cohorts. In non-ICI-sensitive patients, a TMB of ≥15 mut/Mb correlated with improved outcomes (p = 0.012). Mutations in the MYC pathway (p = 0.03) and the MLL2 gene (p = 0.014) were associated with poorer responses, while mutations in the TERT gene were linked to better responses (p = 0.031). Conclusions: Patients without liver metastasis, mutations in TERT, and TMB ≥ 15 mut/Mb are associated with superior response, while mutations in the MYC pathway and MLL2 are associated with worse responses.

  • Open Access

    X-ray Fluorescence Microscopy to Develop Elemental Classifiers and Investigate Elemental Signatures in BALB/c Mouse Intestine a Week after Exposure to 8 Gy of Gamma Rays

    by Anthony Smith, Katrina Dobinda, Si Chen, Peter Zieba, Tatjana Paunesku, Zequn Sun, Gayle E. Woloschak

    Iron redistribution in the intestine after total body irradiation is an established phenomenon. However, in the literature, there are no reports about the use of X-ray fluorescence microscopy or equivalent techniques to generate semi-quantitative 2D maps of iron in sectioned intestine samples from irradiated mice. In this work, we used X-ray fluorescence microscopy (XFM) to map the elemental content of iron as well as phosphorus, sulfur, calcium, copper and zinc in tissue sections of the small intestine from eight-week-old BALB/c male mice that developed gastrointestinal acute radiation syndrome (GI-ARS) in response to exposure to 8 Gray of gamma rays. Seven days after irradiation, we found that the majority of the iron is localized as hot spots in the intercellular regions of the area surrounding crypts and stretching between the outer perimeter of the intestine and the surface cell layer of villi. In addition, this study represents our current efforts to develop elemental cell classifiers that could be used for the automated generation of regions of interest for analyses of X-ray fluorescence maps. Once developed, such a tool will be instrumental for studies of effects of radiation and other toxicants on the elemental content in cells and tissues. While XFM studies cannot be conducted on living organisms, it is possible to envision future scenarios where XFM imaging of single cells sloughed from the human (or rodent) intestine could be used to follow up on the progression of GI-ARS.